The START Study for Early Alzheimer's Disease

Clinical Trial Title

Synaptic Therapy Alzheimer’s Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer’s Disease Over 18 Months

National Clinical Trial Number:

NCT05531656

Contact Information

Clinical Trial Protocol Description:

The START Study is testing an oral investigational treatment to see if it can help slow memory loss caused by Alzheimer’s disease (AD). Scientists believe the investigational treatment works in a different way than other drugs used to treat AD.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are between 50 and 85 years of age.
  • Have mild AD, mild cognitive impairment (MCI), or memory concerns noticed by another person.
  • Have a study partner (such as a spouse, family member, or close friend) willing and able to attend study visits with you and to answer questions about you to study staff.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Neelum T. Aggarwal, MD

Contact Information

Judy Phillips

Clinical Trial Location

ÍÑÒÂÖ±²¥

Location

ÍÑÒÂÖ±²¥

1620 W Harrison St
Chicago, IL 60612

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more